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Summary This report describes the case of an infant suffering from Kawasaki disease with a
concomitant Anaplasma sp. infection. Further studies are required to demonstrate a possible
association between Kawasaki disease and bacterial infections.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Case Report
A 22-month-old girl was admitted to the Pediatric Ward of
Archbishop Makarios Hospital (Nicosia, Cyprus) in August 2007
because of fever, rash and lymphadenopathy for the previous
three days. On physical examination, palpable cervical lymph
nodes more prominent on the right side, rash (maculopapu-
lar), mild non-exudative conjunctivitis and erythematosus
oropharynx were detected. An echo revealed normal anat-
omy and heart function, and normal coronary vessels.
During hospitalization, blood samples were drawn on days
1, 3, 8 and 10. All the results of the biochemical and
hematological tests performed throughout hospitalization
are summarized in Table 1.* Corresponding author. Laboratory of Clinical Bacteriology, Para-
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doi:10.1016/j.ijid.2008.08.001On admission, liver enzymes, direct and total bilirubin,
and the inflammatory markers erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) were raised.
Tests (by PCR and immunofluorescence assay [IFA]) for
cytomegalovirus (CMV), Epstein—Barr virus (EBV), enterovirus,
adenovirus, parvovirus and mycoplasma were all negative, as
was blood culture. Antibodies against Coxiella burnetii phase
II, Rickettsia conorii and Rickettsia typhi were negative, as
were the correspondingPCRamplifications. Antibodies against
Anaplasmaphagocytophilumwere revealed (IgGnegative, IgM
1/20), together with a positive PCR.
The child was initially started on cefuroxime IV. However,
the persistence of fever for longer than five days, and the
development of red cracked lips and desquamation of the
perianal area added Kawasaki disease (KD) and Stevens
Johnson’s syndrome to the differential diagnosis. Therefore,
intravenous immune globulin (IVIG) at a dose of 2 g/kg was
given on day 3 of hospitalization. Despite the fact that the
liver enzymes and bilirubin gradually returned to normal
levels, and the CRP started to decrease after an initialPublished by Elsevier Ltd. All rights reserved.
Table 1 Biochemical and hematological tests performed during hospitalization (Hb: hemoglobin; INR: international normalized
ratio; ALP: alkaline phosphatase; gGT: g-glutamyl transferase; AST: aspartate aminotransferase; ALT: alanine aminotransferase;
LDH: lactate dehydrogenase)
Test [normal values] Day 1 Day 3 Day 8 Day 10
Hb (g/dl) 11 8.5 8.9 10.9
WBC  109/l 17 23 28.5 23
Neutrophils (%) 71 90 85 75
Platelets  103/ul 267 261 280 426
ESR (mm) 61 59 36
CRP (mg/dl) [<0.5] 12 38 11 6
Prothrombin time (s) 17 15 14
INR 1.4 1.29 1.2
Fibrinogen 543 434 347
D-dimers 500—1000 >2000 1000—2000
Urea (mg/dl) [11—25] 20 19 10 14
Creatinine (mg/dl) [0.2—0.9] 0.5 0.4 0.3 0.3
Total protein (g/dl) [5.8—7.2] 7.2 6.3 5.9 7.5
Albumin (g/dl) [4—5] 4.1 2.7 2.4 2.7
Bilirubin total (mg/dl) [0.3—1.2] 6.2 5.4 2.9 1.6
Bilirubin direct (mg/dl) [0.5—1.5] 3.8 2.8 1.4 0.6
ALP (U/L) [74—390] 278 172 147 142
gGT (U/L) [9—35] 153 56 125 129
AST (U/L) [15—40] 255 36 50 28
ALT (U/L) [3—37] 434 99 40 27
LDH (U/L) [260—600] 642 401 485 427
e72 D. Chochlakis et al.increase, the clinical condition of the child did not appear to
improve; the fever and rash persisted and there were still
findings suggestive of liver dysfunction, such as moderately
raised prothrombin time and low albumin. She also started to
have abdominal distention and diarrhea.
As a result, the child was transferred to the Intensive Care
Unit, where the antibiotic treatment was switched to piper-
acillin/tazobactam and vancomycin; later, metronidazole was
also added. Clostridium difficile toxin in stools was negative.
As a result of the persistence of fever and the strong
suspicion of KD, a second course of IVIG was given to the child
on day 8 of hospitalization. ESR and CRP gradually fell,
whereas the platelets increased on day 10 after admission.
WBC count remained high, but the differential changed to
75% instead of 90% (the initial finding). ASTO titer was low.
Chest X-ray and ultrasound of abdomen were normal.
A new echo performed on day 14 of the disease revealed
aneurysms of the coronary vessels. Therefore, the diagnosis
of refractory KD was confirmed and the child was started on
steroids, after which she became afebrile, the rash and other
symptoms resolved, and the laboratory findings returned to
normal.
In a short epidemiological survey, conducted in areas
adjacent to the residence of the patient, 51 samples (41
bovine and 10 sheep) from four flocks were collected and
tested for A. phagocytophilum by PCR and IFA. None of the
samples was positive by PCR. The overall seroprevalence
against the pathogen was 56.8% (29/51), 68% (28/41) bovine
and 10% (1/10) sheep.
All tests were performed at the Archbishop Makarios
Hospital, apart from those concerning C. burnetii, R. conorii,
R. typhi and A. phagocytophilum, which were conducted at
the laboratory of Clinical Bacteriology, Parasitology, Zoo-
noses and Geographical Medicine (Crete, Greece).Regarding the A. phagocytophilum tests, the presence of
IgG and IgM antibodies against the agent in patient serum
samples was detected using indirect IFAwith a commercial kit
(Focus Diagnostics, USA), according to the manufacturer’s
recommendations. IgG titers 1/64 and IgM titers 1/20
were considered positive. DNA extraction from blood samples
was carried out using the QIAamp DNA bloodmini-kit (Qiagen,
Germany). PCR amplification was carried out using the pri-
mer set EHR16SD (GGT-ACC-YAC-AGA-AGA-AGT-CC) and
EHR16SR (TAG-CAC-TCA-TCG-TTT-ACA-GC), targeting a
345 bp fragment of the Anaplasmatic 16s rRNA gene, using
the conditions previously described.1 Distilled water was
used as a negative control.
The animal sera were tested for the presence of IgG
antibodies against A. phagocytophilum antigen by IFA using
a commercial kit (VMRD Inc., Veterinary Medical Research &
Development, USA). IgG titers 1/100 were considered posi-
tive. Regarding animal blood samples, four pools were
formed depending on animal species. DNA extraction and
PCR amplification were carried out as described above.
The positive PCR product was purified using the QIAquick
PCR purification spin kit (Qiagen, Germany) and directly
sequenced using the CEQ 8000 Beckman Coulter sequencer
(BioAnalytica—GenoType, Athens). The sequence revealed
(GenBank accession no. EU448141) was 100% identical to
Anaplasma sp. when compared using nucleotide BLAST
(National Center for Biotechnology Information; http://
www.ncbi.nlm.nih.gov/BLAST).
Discussion
The first description of anaplasmosis in humans was commu-
nicated in the USA in 1994; the first confirmed case in Europe
was described in Slovenia in 1997.2 Since then, a number of
Kawasaki disease and Anaplasma infection e73cases have been described in several European countries,
such as Poland, the Netherlands, Spain, France and so on,3
with Ixodes ricinus being the recognized vector in Europe.4
Anaplasmosis is a clinical syndrome most commonly mani-
fested by non-specific fever, chills, headache and myalgias.
Leukopenia, a left shift, thrombocytopenia and hepatic
transaminase elevations are present in the majority of
patients. Infection by the pathogen can be severe, with
nearly half of patients requiring hospitalization.5 The diag-
nosis can be confirmed by PCR, especially during early infec-
tion when antibodies are not yet detectable.6 The
recommended therapy for adults is 100 mg doxycycline given
orally at 12-hour intervals.5
KD was first described and reported by Tomisaku Kawasaki
in 1967.7 It is an acute febrile multisystem vasculitis that
almost exclusively affects infants and young children. The
diagnosis of KD is considered to be confirmed by the presence
of fever for five days and four of the remaining five criteria: 1)
bilateral conjunctival injection; 2) changes of the mucous
membranes of the upper respiratory tract: injected pharynx,
injected fissured lips, strawberry tongue; 3) changes of the
peripheral extremities: peripheral edema, peripheral
erythema, periungual desquamation; 4) polymorphous rash;
and 5) cervical adenopathy.8 Furthermore, there must be no
alternative explanation of the findings. As regards therapy for
the disease, in 1988 the Committee on Infectious Diseases of
the American Academy of Pediatrics endorsed IVIG treatment
as the recommended therapy for children with acute KD.9
The cause of KD remains unknown, although recent stu-
dies suggest that exposure to an infectious agent in a geneti-
cally vulnerable child is required for the pathogenesis of KD.
It is hypothesized that a non-specific immune activation
triggered by various agents might constitute the common
pathway for the manifestation of the disease. The assump-
tion of the association of an infectious agent is based on
several observations. These include a seasonal peak in the
winter to spring months in most geographical areas; epi-
demics with a clear epicenter, the peak incidence in certain
age groups, with only rare cases in infants, three-month-olds
and adults, suggesting a role for transplacental antibodies in
conferring protection; and the similarity of many of the
clinical features of KD to those of other infectious diseases.10
The idea postulated is that bacterial toxins act as super-
antigens that can trigger the cascade of events that even-
tually leads to KD. Despite several disputes, attempts have
been made to implicate bacterial agents, such as Bartonella
sp. and Ehrlichia,11 C. burnetii, R. conorii and R. typhi.12Nevertheless, no specific microorganism has been consis-
tently detected in children with KD, making the above
hypothesis a controversial one.
To our knowledge, this is the first report describing a case
of KD with a concomitant infection by Anaplasma sp. con-
firmed by PCR. Although no association between bacterial
infection and KD can be proven by this case, this report
reveals once more the need for the investigation of the
underlying cause of KD.
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